

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	10/634,979
Filing Date	08-05-2003
First Named Inventor	STROBEL
Group Art Unit	
Examiner Name	Not Yet Known
Attorney Docket Number	DEAV2002/0056 - US - NP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office ³	Number ⁴	Kind Code ⁵ (If known)				
EP ↑ ↓ EP	✓	EP	EP 1 277 729 A1	P	AMEMIYA et al	01-22-2003		
	✓	WO	WO 00/03746	P	LIAO	01-27-2000		
	✓	WO	WO 00/27394	P	SELWOOD et al	05-18-2000		
	✓	WO	WO 00/27819	P	HUTH et al	05-18-2000		
	✓	WO	WO 01/97786	P	ALANINE et al	12-27-2001		
	✓	WO	WO 02/064545 A1	P	STROBEL et al	08-22-2002		
	✓	WO	WO 02/064546 A2	P	STROBEL et al	08-22-2002		
	✓	WO	WO 02/064565 A1	P	STROBEL et al	08-22-2002		
	✓	WO	WO 02/34711 A1	P	BABU et al	05-02-2002		
✓	WO	WO 99/47153	P	LIAO	09-23-1999			

**Examiner
Signature**

Fiona T. Powers

Date _____

Considered

1/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

SEP 29 2008

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/634,979
				Filing Date	08-05-2003
				First Named Inventor	STROBEL
				Group Art Unit	
				Examiner Name	Not Yet Known
Sheet	2	of	5	Attorney Docket Number	DEAV2002/0056 - US - NP


[illegible][illegible]

Examiner Signature	<i>Fiona T. Powers</i>	Date Considered	<i>1/11/06</i>
-----------------------	------------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Compleat if Kn wn		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/634,979	
			Filing Date	08-05-2003	
			First Named Inventor	STROBEL	
			Group Art Unit		
			Examiner Name	Not Yet Known	
Sheet	3	of	5	Attorney Docket Number	DEAV2002/0056 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JTP	✓	BELLASIO E et al., Sostanze A Potenziale Azione Cardiovascolare. 2-acilaminobenzimidazoli ad attivita ipotensiva, Farmaco, Ed. Sc., Vol. 28, 2, 1978, pp 164-182	
	✓	BOGOSLOWSKII et al, Synthesis of some Derivatives of Aminoquinolines, Zhurnal Obshchel Khimii; Vol.14; 1944; pp.316-318.	
	✓	BUSCEMI et al, Heterocyclic Photorearrangements. Photochemical Behaviour of Some 3,5-Disubstituted 1,2,4-Oxadiazoles in Methanol at 254 nm., Journal of Heterocyclic Chem.; Vol. 25; May-June 1988; pp.931-935	
	✓	BUSCEMI et al., Heterocyclic Photorearrangements. Photoinduced Rearrangements of 1,2,4-Oxadiazoles Substituted by an XYZ Side Chain Sequence, Journal of Heterocyclic Chem.; Vol. 25; Sept-Oct. 1988; pp.1551-1553.	
	✓	ELINA et al, Tautomerism of 2-Acetylaminoquinoxalines and Their N-Oxides, Chem. Heterocyclic Compd.(Eng. transl.); No.2; 1966; pp.72-76. .	
	✓	ENDRES M et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Aca. Sci. USA 95, 1998, Vol. 95, pp 8880-8885	
	✓	HARSANYI et al, Redox-Aromatisierung des 2-Oximino-1.2.3.4-tetrahydrochinoxalins und seiner Acylderivate, Chem. Ber.; No.105; 1972; pp.813-819.	
	✓	KHRISTICH et al, The Benzoylation of 2-Amino-1-Methylbenzimidazole, Chem. Heterocycl. Compd. (Eng. Transl.); No. 9; 1973; pg.1174.	
	✓	KHRISTICH, B.I., et al., Synthesis and Transformations of 2-Amino-3-Acyl-1-Methylbenzimidazolium Salts, Chemistry of Heterocyclic Compounds (Eng. Translation), No. 10, October 1974, pp. 1225-1228.	
JTP	✓	LAUFS Ulrich et al., Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors, Circulation 97, 1998, pp 1129-1135	

Examiner Signature	Lorna T. Powers	Date Considered	1/11/06
-----------------------	-----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/634,979
			Filing Date	08-05-2003
			First Named Inventor	STROBEL
			Group Art Unit	
			Examiner Name	Not Yet Known
			Attorney Docket Number	DEAV2002/0056 - US - NP
Sheet	4	of	5	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FTP	✓	LI Huijie et al., Activation of Protein Kinase C(alpha) and/or (epsilon) Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, Vol. 53, pp 630-637	
	✓	MOROI Masao et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, J. Clin. Invest., 1998, Vol. 101, No. 6, pp 1225-1232	
	✓	NAKAYAMA Masafumi et al., T-786---->C Mutation in the 5'-Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated with Coronary Spasm, Clinical Investigation and Reports, Circulation 99, 1999, pp 2864-2870	
	✓	PILYUGIN V.S., et al., Synthesis and Biological Activity of Derivatives of 2-Aminobenzimidazole and Carboxylic Acids (Eng. translation), Bashk. Khim. Zh. 2001, Tom 8, No. 1, pp 18-25	
	✓	POPOV et al, Condensation of 2-Aminobenzimidazoles with o-Substituted Benzoyl Chlorides, Chem. Heterocyclic Comp. (Eng. Transl.); Vol.25(2); 1989; pp.229.	
	✓	RAO et al, Synthesis of 2-Aryl-1H-s-Triazolo[1,5-a]Benzimidazoles, Synthetic Communications; No.18; 1988; pp.1995-2001.	
	✓	SESSA William C et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 1994, Vol. 74, No. 2, pp 349-353	
	✓	SHEPARD et al, Carboxylic N,N-Diphenylcarbamic Anhydrides, New Acylating Agents, Journal Heterocyclic Chem.; No.16; 1979; pp.321-325.	
	✓	SHIOKAWA et al, Studies on Benzimidazoles and related Compounds. IV. Reactivity of 2-Azido-1-methylbenzimidazole, Chem. Pharm. Bulletin; No.19; 1971; pp.401-408.	
FTP	✓	SIMONOV M., et al., Derivatives of 2-Amino-1-Methylbenzimidazole-5-Carboxylic Acid, Journal of General Chemistry of the USSR (Eng. translation), V32, 1962, pp.2194-2196.	

Examiner Signature	<i>Fiona T. Powers</i>	Date Considered	1/11/06
--------------------	------------------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-95)
Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			C m p l t I f K n w n	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/634,979
			Filing Date	08-05-2003
			First Named Inventor	STROBEL
			Group Art Unit	
			Examiner Name	Not Yet Known
			Attorney Docket Number	DEAV2002/0056 - US - NP
Sheet	5	of	5	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FTP	✓	TAKAHASHI et al, 1,3-Dipolar Cycloaddition Reaction with 1-Methylbenzimidazole 3-Oxide, Tetrahedron Letters; No.25; 1963; pp.1687-1691.	
	✓	TAKAHASHI et al, Benzimidazole N-Oxides. IV. 1,3-Dipolar Cycloaddition Reaction with 1-Methylbenzimidazole 3-Oxide, Chem. Pharm. Bull.; Vol.12; 1964; pp.1290-1295.	
	✓	TAMURA et al, Syntheses and Properties of 3-Acylimino-1-alkylimidazolium and Benzimidazolium Betaines, Journal Heterocyclic Chem.; Vol. 11; 1974; pp.781-785.	
	✓	VAN ALLEN et al, The Reaction of Certain Heterocyclic Azides and triphenylphosphine, Journal Heterocyclic Chem; No. 5; Aug. 1968; pp.471-476.	
	✓	VARENNE Olivier et al., Percutaneous Gene Thereapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Procline Coronary Arteries, Human Gene Thereapy,2000, Vol. 11, pp 1329-1339	
	✓	WOLF et al, Substituted Sulfaquinoxalines. Extension of the Glyoxalate Synthesis of 2-Aminoquinoxaline, J. Amer. Chem. Soc.; Vol.71; 1949; pp.6-8.	
FTP	✓	WOLF et al, Substituted Sulfaquinoxalines. Some Derivatives and Isomers of 2-Sulfanilamidoquinoxaline, J. Amer. Chem. Soc.; Vol.70; 1948; pg.2572.	

Examiner Signature	<i>Arona T. Powers</i>	Date Considered	1/11/06
-----------------------	------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

